David Hulcoop appointed Open Targets Director

5 July 2023

July 5, Cambridge — Open Targets has appointed David Hulcoop as its new Executive Director, following the retirement of Ian Dunham. Hulcoop will build from the programme’s existing capabilities to maximise Open Targets impact on drug discovery decision making.

Open Targets, a public-private partnership founded in 2014, aims to use the information generated by genome sequencing and genetics studies to systematically improve the identification and prioritisation of drug target...

Read more

Open Targets project creates a human interactome to prioritise drug discovery

23 February 2023

Scientists at Open Targets, EMBL’s European Bioinformatics Institute (EMBL-EBI), and GSK are revealing the shared basis of diseases using a map of interacting human proteins. By helping to understand how biological processes affect human traits and diseases, this work will prioritise new targets for drug discovery and identify drug repurposing opportunities.

Proteins are molecules that do most of the work in our cells and are made following blueprints encoded in genes. They are ess...

Read more

Bowel cancer mutations that impact immunotherapy identified

19 January 2023

Researchers used CRISPR and mini tumours to discover more about how cancer develops and responds to the body’s immune response.

A new library documenting hundreds of mutations can help to explain why some cancers don’t respond to immunotherapies, and highlights potential pathways that could be drug targets in the future.

The researchers, from the Wellcome Sanger Institute, Open Targets, and collaborators, used CRISPR gene editing technology and mini tumours...

Read more

Open Targets consortium welcomes Genentech as newest member

14 November 2022

Open Targets announced today that Genentech, a member of the Roche Group, has joined the consortium, which identifies, prioritises, and validates drug targets to accelerate the development of safe and effective medicines. The second company to join the industry-academic partnership this year, Genentech will collaborate with other consortium members including EMBL’s European Bioinformatics Institute (EMBL-EBI), the Wellcome Sanger Institute, GSK, Bristol Myers Squibb, Sanofi, and Pfizer.

Read more

Study tracking T-cell activation over time boosts search for immune disease treatments

26 May 2022

In a first-of-its-kind experiment, researchers have identified links between 127 genes and immune diseases, providing newfound insights into the sequence and timing of gene activity during the activation of T cells, a key process in regulating the body’s immune response.

The study, led by researchers from Open Targets, the Wellcome Sanger Institute and GSK, is published today (26 May 2022) in Nature Genetics. The result of a 3 year research effort, it is the first to show that nume...

Read more

Pfizer joins the Open Targets consortium

14 February 2022

Open Targets, a consortium focused on drug target identification, prioritisation, and validation, announced today that Pfizer has joined as a partner. Pfizer will contribute its unique expertise in oncology, immunology, and metabolic disorders as part of the innovative public-private partnership which uses human genetics and genomics data with the aim of improving the success rate for developing new medicines. This complements the strengths of the five current partners: EMBL’s European Bio...

Read more

Locus-to-Gene method published in Nature Genetics

28 October 2021

Our locus-to-gene (L2G) machine learning scoring method was published in Nature Genetics (the preprint is also available). The L2G score reflects the likelihood that a gene is causal for the trait in question, allowing genes at trait-associated loci to be ranked by the relative strength of their evidence. It has been included in the Genetics portal since version 4.

Read more

Open Targets releases a COVID-19 Target Prioritisation Tool

29 July 2020

Open Targets is excited to announce the release of our COVID-19 Target Prioritisation Tool, an interactive, open source web portal that integrates a number of key public datasets and publications to facilitate systematic exploration of host and viral targets as well as potential treatments for COVID-19.

Read more

Open Targets Helix logo and wordmark

Gosia Trynka awarded 2020 Leena Peltonen Prize

6 June 2020

Open Targets is excited to announce that Gosia Trynka, our Experimental Science Director, has been awarded the 2020 Leena Peltonen prize by the European Society for Human Genetics (ESHG).

The prize is given every two years to an outstanding young researcher in the field of human genetics and it honours the memory of Dr. ...

Read more